biodiversidad (@_biodiversa) header
biodiversidad (@_biodiversa) profile picture

#wetware: conservación, tecnología, economía de genes. reservas estratégicas de ADN. mercados de información. economía post-genómica, post-petrolera

California, Ecuador
Joined May 2012
Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)Photo by biodiversidad (@_biodiversa)
biodiversidad retweeted
Monsanto Canada Inc. v. Schmeiser decisions.scc-csc.ca/scc-csc… the new oil teapawt.net/_biodiversa/status/160… patents, risk teapawt.net/_biodiversa/status/160… digital sequence information #DSI
what is the legal definition of "genetic resource" and "digital sequence information"? what does "as applicable" mean? who defines fairness and equitability? patents, risk? teapawt.net/_biodiversa/status/160… @OscarALizarazo @KlausRiede @synbiomaria @aysirakaya @Basecamp_Res thanks!
1
3
1
2
286
biodiversidad retweeted
Aichi Target 5: habitat loss, not achieved teapawt.net/_biodiversa/status/139… royalties as low as 0.01%, gene patents teapawt.net/_biodiversa/status/150… bioeconomy, US$0.5-1.4 trillion teapawt.net/LBNLBioSci/status/1359… industria del ADN teapawt.net/_biodiversa/status/149… #DSI #Nagoya
A new #BioScience Viewpoint offers community-generated recommendations for enabling effective access and benefit sharing of digital sequence information.#aibs #journal academic.oup.com/bioscience/…
biodiversidad retweeted
Yes
Biotech still runs on who owns the patent and who approves the drug. That was my takeaway from @alexkesin's session at DataDrivenPharma West last week. Alex wrote one of the most widely shared analyses of China's biotech rise this year, and it has become a reference point in the policy debate. He also co-hosts @approvedfm with [@MatthewPech], a podcast on how drugs get discovered, developed and sold. He walked a room of operators through where the value sits now. Four quick hits: - 1:3. Doing the work in China costs a half to a third of the US price. - Rent, don't sell. Beijing's new export controls block the sale of biotech platforms. Licensing, partnerships and contract research stay open. - 3x. China tripled its university patent conversion rate in two years, to 10.1%. - 8% to 32%. China's share of the global early-stage pipeline, from 2015 to 2024. The first hit explains the last five years. China got cheap and fast, and the West bought what it built. Most of those deals were fast-follows on targets Western labs discovered. The West owned the original IP and rented China's speed. The other three point to the next five. The export controls dropped the same morning as the session. Read them next to the new five-year plan, which makes biotech and biomanufacturing a national priority through 2030. The strategy looks clear to me. Generate IP faster than the US, keep ownership at home, and let the world license it. Pipeline share has quadrupled. Patents are moving out of universities and into companies. Nine out of ten still sit unused, so there's plenty of room to grow. Patents are still the currency. Regulators still set the exchange rate. The FDA turned away a Chinese PD-1 copycat because its trial ran only on Chinese patients. To get paid in the US, you still need FDA approval and a partner who can launch here. What changes is who holds the paper. When the West generated the IP, licensing meant Western companies owned the value and paid for speed. As more IP is generated and kept in China, the same deal structure sends more value the other way. The West ends up renting the molecule instead of owning it. This is a gold rush for intellectual property. The question is who can generate novel IP in a specific area, and do it first. Therapeutics is the beachhead. The US market pays enough for new drugs that the long road through the FDA still earns a return. In this gold rush, anyone can be a miner. The fastest ones will have the best maps. And maps only come from data. #ddpwest26
3
10
1,060
Amazon’s new AI Bio Discovery tool can provide ‘every researcher’ with ‘lab-in-the-loop drug discovery’ – 40+ AI biology models can filter 300,000 novel antibody candidates down to the top results for testing in just weeks | @techradar techradar.com/pro/amazons-ne…
2
2
682
biodiversidad retweeted
14 (a) Should economic rent be charged for access to genetic resources? What should be the basis for the valuation of such rent? cbd.int/decision/cop?id=1165… Ozempic, ~US$14 billion qz.com/ozempic-weight-loss-d… digital sequence information #DSI
Replying to @_biodiversa
Enclosure A (a) Pharmaceuticals; (d) Biotechnology; (f) Information, scientific, technical services related to #DSI on genetic resources including AI (?) cbd.int/doc/c/8125/22ca/baa2… IP, risk teapawt.net/_biodiversa/status/180…
1
1
28
biodiversidad retweeted
The synthetic biology revolution is upon us, and its TRILLIONs of dollars of value to be created. SynBioBeta has their conference again in Oakland May 23-25 I urge you to go or to follow what is happening. forbes.com/sites/johncumbers…
44
120
32
558
126,350
biodiversidad retweeted
predict lab-of-origin of engineered DNA nature.com/articles/s41467-0… country of origin? countries exercise sovereign rights over genetic resources teapawt.net/_biodiversa/status/128… those prized genes can be assembled in a laboratory to churn out anything teapawt.net/_biodiversa/status/125… #DSI #Nagoya
drivendata.org/competitions/… Your goal is to create an algorithm that identifies the most likely lab-of-origin for genetically engineered DNA.
2
3
biodiversidad retweeted
genome privacy teapawt.net/_biodiversa/status/165… digital sequence information #DSI
#BioNFTs 🧬 (thread 🧵): 1/ #BioNFTs are a new way for patients to own and control their biosample-derived data, such as #DNA, in a centralized or decentralized storage protocol.
2
3
133
biodiversidad retweeted
DNA-based watermarks are helpful tools to identify the unauthorized use of genetically modified organisms (GMOs) protected by patents bmcmolbiol.biomedcentral.com…
Labeling genes and genetically modified organisms with DNA watermarks biopharminternational.com/vi… tracking, paying for genes teapawt.net/_biodiversa/status/150… #DSI #Nagoya #COP15
1
2
biodiversidad retweeted
How big is the #bioeconomy in money? 0.5 to 1.4 trillion US dollars, Jeff Furman says. #AAASmtg @BUQuestrom
biodiversidad retweeted
12,998 #DSI, 862 species. BASF: 47% of gene patents, universities: 12%. 10 countries registered 98% of all gene patents, 165 countries unrepresented. science.org/doi/10.1126/scia… Who Owns the Rights to Wonder Plants? e360.yale.edu/features/indig… #Nagoya
"Navigating access and benefit-sharing of plant genetic resources and digital sequence information" #DSI benefits must be distributed equitably in a way that supports biodiversity conservation & enables research progress & innovation. 9 videos playlist 👉buff.ly/3JhR2J4
1
1
biodiversidad retweeted
California Attorney General Rob Bonta sued the genetic testing company formerly known as 23andMe over its handling of a 2023 data breach that exposed nearly 7 million users’ sensitive personal information, including genetic data. news.bloomberglaw.com/privac…
2
2
1
5
992
biodiversidad retweeted
Every country holds their rights over plants, animals and genetic resources that are found in its borders. This was agreed upon in #Rio in 1992.🌿 Through #ABS the rights of countries and local communities are respected for a fair use of #geneticresources. 🧬⚖️@UNBiodiversity
The #AcccessAndBenefitSharing 🤝or ABS principle is the third objective of the Convention of Biological Diversity. Watch @ABSBiotrade's video that simply explains the ABS principle and the #NagoyaProtocol: youtube.com/watch?v=09zflWUI… #theABSweALLneed
1
5
1
8
biodiversidad retweeted
#GiveGenesAChance! In 2023 the EU commission will release a draft of a new regulation for gene-edited crops for debate. Give Genes A Chance (@GGAChance) will be following this process, building a network of young scientists across Europe and giving them a voice. 💚🧬 #synbio
biodiversidad retweeted
royalties as low as 0.01% for use of genetic resources resulting in intellectual property teapawt.net/_biodiversa/status/150… 47% of gene patents teapawt.net/_biodiversa/status/150… next-generation biotechnologies remain vastly unexplored teapawt.net/_biodiversa/status/150… #DSI #Nagoya
Sign your name now to voice your support for international polices on digital sequence information that protect #openscience, increase benefit-sharing, and promote research that helps protect and conserve #biodiversity dsiscientificnetwork.org/ope… #openDSI
biodiversidad retweeted
Enclosure A (a) Pharmaceuticals; (d) Biotechnology; (f) Information, scientific, technical services related to #DSI on genetic resources including AI (?) cbd.int/doc/c/8125/22ca/baa2… IP, risk teapawt.net/_biodiversa/status/180…
1
1
1
61